Medicenna Therapeutics (TSE:MDNA) Trading Down 2.2% – What’s Next?

Medicenna Therapeutics Corp. (TSE:MDNA) shares fell 2.2% during trading on Tuesday . The stock traded as low as C$0.88 and last traded at C$0.88. 74,527 shares traded hands during trading, a decline of 49% from the average session volume of 146,412 shares. The stock had previously closed at C$0.90.

Medicenna Therapeutics Trading Down 2.2%

The company has a fifty day simple moving average of C$1.15 and a two-hundred day simple moving average of C$1.10. The company has a debt-to-equity ratio of 0.88, a current ratio of 11.40 and a quick ratio of 4.65. The company has a market capitalization of C$73.40 million, a P/E ratio of -5.18 and a beta of 3.37.

Medicenna Therapeutics (TSE:MDNA) last posted its earnings results on Thursday, November 13th. The company reported C($0.06) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 159.88%. On average, analysts forecast that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.